Nanobiotix (NBTX) Peer Comparison
$45.16
$0.66
(1.48%)
As on 27-Aug-2026 16:10EDT
Market cap
$2,213 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
65
Div. Yield
0 %
Edit
| Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
2,213 | 1,862 | 1,106 | 660 | 252 |
Revenue (€ Mln) |
30 | 1,044 | 4 | 144 | 3 |
Net Profit (€ Mln) |
-23.96 | 488.78 | -340.16 | -158.17 | -49.18 |
Net Margin (%) |
-- | 46.83 | -540.52 | -110.21 | -72.76 |
RoE (%) |
31.91 | 15.95 | 501.41 | -168.93 | 764.76 |
Price to Earnings |
-- | 3.18 | -- | -- | -- |
Price-To-Book |
65.02 | 0.49 | 2.10 | 6.89 | 20.10 |
Income Statement (€ Mln)
| Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
29.64 | 1,112.25 | 4.48 | 174.66 | 2.79 |
|
Cost of Revenue
|
-- | 29.74 | 2.80 | 107.14 | -- |
|
Gross Profit
|
29.64 | 1,082.51 | 1.51 | 67.52 | 2.79 |
|
Operating Expenses
|
40.46 | 581.12 | 137.37 | 149.15 | 56.21 |
|
Operating Profit (EBIT)
|
-10.82 | 501.39 | -130.95 | -81.63 | -53.43 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-23.96 | 300.87 | -342.33 | -114.12 | -49.18 |
|
Provision for Tax
|
0.00 | -18.62 | 0.02 | 1.07 | -5.96 |
|
Profit after Tax (Net Income)
|
-23.96 | 320.88 | -340.16 | -115.19 | -49.18 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities (€ Mln)
| Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-84.48 | 3,234.49 | -29.04 | 106.17 | -21.69 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
94.74 | 17.78 | 200.57 | 199.33 | 47.75 |
|
Current Liabilities
|
57.51 | 152.80 | 77.35 | 93.33 | 36.63 |
|
Total Liabilities
|
67.76 | 3,405.07 | 248.88 | 398.84 | 62.69 |
Assets (€ Mln)
| Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
5.01 | 326.92 | 5.04 | 176.30 | 16.00 |
|
Current Assets
|
62.75 | 3,078.15 | 243.84 | 222.54 | 46.69 |
|
Total Assets
|
67.76 | 3,405.07 | 248.88 | 398.84 | 62.69 |
|
Total Debt*
|
95.32 | 6.92 | 59.40 | 207.25 | 22.56 |
|
Net Current Assets
|
5.24 | 2,926.59 | 167.09 | 129.21 | 10.06 |
Cashflow (€ Mln)
| Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-33.42 | -189.23 | -100.98 | -52.89 | -32.56 |
|
Cash Flow from Investing Activities
|
-0.58 | 219.35 | -127.93 | -1.71 | 20.63 |
|
Cash from Financing Activities
|
37.42 | -3.14 | 232.00 | -0.62 | -1.97 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
1,208.63 | 10.44 | 3,098.72 | -32.40 | -241.67 |
|
ROE (%)
|
31.91 | 10.47 | 501.41 | -80.16 | 764.76 |
|
ROA (%)
|
-35.45 | 8.51 | -184.95 | -25.63 | -56.61 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-80.83 | 28.85 | -7,587.80 | -65.95 | -1,764.51 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
5.12 | 3.04 | -0.51 | 0.03 | -0.78 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
64.83 | 333.15 | -84.66 | -840.57 | 0.59 |
|
EPS Growth (%)
|
0.65 | 3.39 | 0.85 | -6.62 | 0.12 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-46.14 | 6.71 | -8.71 | -6.64 | -3.25 |
|
Price / Book Value
|
-13.09 | 0.67 | -102.03 | 7.20 | -7.37 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-95.14 | -2.33 | -21.78 | -17.09 | -3.40 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.13 | 0.00 | -2.05 | 1.95 | -1.04 |
|
Short term debt to equity ratio
|
-0.05 | 0.00 | -1.11 | 0.19 | -0.41 |
|
Current Ratio
|
1.09 | 20.15 | 3.15 | 2.38 | 1.27 |
|
Quick Ratio
|
-- | 20.00 | 3.15 | 1.85 | -- |
|
Interest Coverage
|
-1.30 | 136.71 | -4.05 | -1.72 | -110.77 |
Operating Efficiency Ratios
| Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | Valneva SE - ADR | Innate Pharma S.A. ADS - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
25.91 | 4.78 | 203.37 | 15.92 | 273.05 |
|
Asset Turnover
|
0.44 | 0.29 | 0.02 | 0.39 | 0.03 |
|
Receivable days
|
99.90 | 16.53 | 866.65 | 65.89 | 606.33 |
|
Inventory Days
|
-- | 452.54 | 0.00 | 177.10 | -- |
|
Payable days
|
-- | 1,242.94 | 3,844.90 | 37.01 | -- |
|
Cash Conversion Cycle
|
-- | -773.87 | -2,978.25 | 205.98 | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
